A Non-Injectable Short-Acting Insulin for Type 1 Diabetes With Significantly Improved Efficacy Over Insulin Aspart Would Earn a Higher Patient Share in Europe Than in the United States
Posted on: Thursday, 29 January 2009, 08:00 CST
MannKind's Technosphere Used in Conjunction With Insulin Glargine Will Earn Decision Resources' Clinical Gold Standard in 2012, According to a New Report from Decision Resources
The new report entitled Type 1 Diabetes: Opportunities Await Therapies That Offer Alternatives to Subcutaneous Injections of Insulins finds that interviewed endocrinologists are excited about Andromeda Biotech/DeveloGen's DiaPep 277, as it will potentially be the first safe disease modifying agent to reach the market for the treatment of type 1 diabetes. Although DiaPep 277 will not obviate the need for insulin injections, the maintenance of pancreatic beta cell function is anticipated to result in improved overall glycemic control for patients, together with reduced risk for hypoglycemia.
Basal-bolus insulin therapy using a regimen of insulin glargine (Sanofi-Aventis's Lantus) and a short-acting insulin analogue (Novo Nordisk's NovoRapid/NovoLog, Eli Lilly's Humalog) is Decision Resources' proprietary clinical gold standard for 2009. Following its anticipated approval for this indication in 2012, MannKind's Technosphere will replace the short-acting insulins as the new clinical gold standard for type 1 diabetes.
"In clinical trials, Technosphere has demonstrated a faster and more physiological action profile than insulin lispro or insulin aspart," said Decision Resources Analyst
About the Report
Type 1 Diabetes: Opportunities Await Therapies That Offer Alternatives to Subcutaneous Injections of Insulins is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
- Doctors Believe Insulin Pump Therapy is Preferable to Insulin Injections for Managing Diabetes, Says Survey
- Nektar Reports Pfizer Announcement That New Studies Show More Than Half of Patients at Risk for or Suffering From Complications of Type 2 Diabetes Delay Insulin Injections -- Some More Than Four Years
- Diabetes Research Breakthrough Expected to End Insulin Injections
- Risk Factors for Type 2 Diabetes in Women Attending Menopause Clinics in Italy: a Cross-Sectional Study
- American Diabetes Association: Diabetes School Care Act Significant Step in Meeting Medical and Educational Needs of Texas Students With Diabetes
- Regular Use of Corticosteroids and Low Use of Short-Acting [Beta]^Sub 2^-Agonists Can Reduce Asthma Hospitalization*
- Plasma Glucose Responses in Recreational Divers With Insulin- Requiring Diabetes
- The CORE Diabetes Model: Projecting Long-Term Clinical Outcomes, Costs and Cost-Effectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision- Making
 |
 |
User Comments (0)
RSS Feeds